title: Increase of bone alkaline phosphatase after androgen deprivation therapy in patients with prostate cancer.
abstract: OBJECTIVE
  To evaluate the behavior of bone alkaline phosphatase (BAP) after androgen deprivation therapy in patients with prostate cancer.
  
  
  METHODS
  BAP was determined in the serum of 35 patients with nonmetastatic prostate cancer before maximal androgen blockade. During 5 years of follow-up, BAP was determined annually. A subset of 36 patients who underwent radical prostatectomy as the only treatment for prostate cancer was selected as a control group.
  
  
  RESULTS
  The mean pretreatment BAP serum concentration was similar in both groups (10.8 and 10.4 ng/mL, P >0.05). However, after 5 years, the mean BAP serum concentration increased 64.8% in the study group (from 10.8 to 17.6 ng/mL, P < 0.001); it remained stable in the control group (from 10.4 to 10.4 ng/mL). The increase of serum BAP in patients receiving androgen deprivation was 32.4% during the first year (from 10.8 to 14.3 ng/ml), 16.7% during the second (from 14.3 to 16.1 ng/mL), 7.4% during the third (from 16.1 to 16.9 ng/mL), 5.5% during the fourth (from 16.9 to 17.3 ng/mL), and 2.8% during the fifth year (from 17.3 to 17.6 ng/mL).
  
  
  CONCLUSIONS
  Androgen deprivation produces an increase in the BAP serum concentration. A major increase seems to be produced during the first year of follow-up and thereafter this increase is reduced around 50% annually.
authors.affiliation: Department of Urology, Vall d'Hebron Hospital and Autónoma University School of Medicine, Barcelona, Spain.
authors.forename: Juan
authors.initials: J
authors.lastname: Morote
authors.forename: Youssef I D
authors.initials: YI
authors.lastname: M'Hammed
authors.forename: Esther
authors.initials: E
authors.lastname: Martinez
authors.forename: Salvador
authors.initials: S
authors.lastname: Esquena
authors.forename: Jose Antonio
authors.initials: JA
authors.lastname: Lorente
authors.forename: Antonio
authors.initials: A
authors.lastname: Gelabert
mesh_terms: D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood*; D000726:Androgen Antagonists / Q000627:therapeutic use*; D016022:Case-Control Studies; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood* / Q000601:surgery / Q000628:therapy
chemical_list: D000726:Androgen Antagonists; D000469:Alkaline Phosphatase